Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland

Published on: 

Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.

Thermo Fisher Scientific announced that it had opened a new biologics manufacturing site in Lengnau, Switzerland on Oct. 1, 2021. Thermo Fisher assumed operational responsibility of the facility as a result of their strategic partnership with CSL Limited, a biotechnology company, that was announced in 2020.

The Lengnau site is a 1.5 million ft² biologics facility with up to 12,500 L of bioreactor capacity. It joins Thermo Fisher’s biologics manufacturing network that includes Princeton, NJ, St. Louis, MO, Groningen, The Netherlands, Brisbane, Australia, and Hangzhou, China.

Following completion of on-site construction in 2022, the facility will initially manufacture CSL’s next-generation recombinant factor IX product Idelvion for patients with hemophilia B. In addition to this production, Thermo Fisher plans to expand site use to accommodate other biopharma customers in the future.


"We are excited to add the new Lengnau site to our global biologics manufacturing network and we are thrilled to welcome more than 200 new colleagues to Thermo Fisher," said Michel Lagarde, executive vice-president of Thermo Fisher Scientific, in a company press release. "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow."

Source: Thermo Fisher Scientific